Stress, Diurnal Cortisol, and Breast Cancer Survival

Breast Cancer Clinical Trial

Official title:

Stress, Diurnal Cortisol, and Breast Cancer Survival

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00226967
• Other study ID #: IRB-12273
• Secondary ID: 76389BRSADJ0006
• Status: Completed
• Start date: September 8, 2002
• Est. completion date: December 2005

Study information

• Verified date: February 2019
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to learn about the effects of stress on hormones, the relationship between these hormones and cancer progression.

Description:

The purpose of this study is to investigate stress and tonic activation of diurnal cortisol in aging metastatic breast cancer patients; feedback inhibition & activation of cortisol; and stress-induced phasic activation of cortisol.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 115
• Est. completion date: December 2005
• Est. primary completion date: November 2004
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 35 Years and older

Eligibility

Inclusion Criteria:

1. Diagnosis of recurrent or metastatic breast cancer.

2. Karnofsky of 70% or greater.

3. Proficient enough in English to be able to take questionnaires and participate in the required tasks.

4. Living within the Greater Bay Area.

5. Age 35 or older .

Exclusion Criteria:

1. Positive supraclavicular lymph nodes as the only metastatic lesion at the time of initial diagnosis.

2. Active cancers within the past 10 years other than breast cancer, basal cell or squamous cell carcinomas of the skin, or in situ cancer of the cervix.

3. Any other serious medical condition that will effect short term survival

4. History of major psychiatric illness for which patient was hospitalized or medicated, with the exception of depression or anxiety

5. A diagnosis of diabetes.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Drug:
• Sandostatin
Calculated per patient

Locations

Country	Name	City	State
United States	Stanford University School of Medicine	Stanford	California

Sponsors (2)

Lead Sponsor	Collaborator
Stanford University	National Institute on Aging (NIA)

Country where clinical trial is conducted

United States,